Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. April 2020 19:00 ET | Quelle: MediciNova, Inc.

MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

LA JOLLA, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
08. April 2020 06:07 ET | Quelle: MediciNova, Inc.

MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)

LA JOLLA, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
09. März 2020 19:00 ET | Quelle: MediciNova, Inc.

MediciNova Announces Plans to Develop MN-166 (ibudilast) for Severe Pneumonia and Acute Respiratory Distress Syndrome (ARDS)

LA JOLLA, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
17. Februar 2020 18:00 ET | Quelle: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan

LA JOLLA, Calif., Feb. 17, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
27. Januar 2020 18:00 ET | Quelle: MediciNova, Inc.

MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe

LA JOLLA, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
04. Dezember 2019 18:00 ET | Quelle: MediciNova, Inc.

MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th International Symposium on ALS/MND in Perth, Australia

LA JOLLA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
28. Oktober 2019 06:00 ET | Quelle: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

LA JOLLA, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
23. Oktober 2019 06:00 ET | Quelle: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan

LA JOLLA, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
07. Oktober 2019 19:00 ET | Quelle: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan

LA JOLLA, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
30. September 2019 19:00 ET | Quelle: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China

LA JOLLA, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...

Vorherige Seite

Nächste Seite